These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2106188)

  • 1. Failure of pyridostigmine to increase both basal and GHRH-induced GH secretion in the night.
    Ghigo E; Arvat E; Mazza E; Mondardini A; Cappa M; Müller EE; Cammani F
    Acta Endocrinol (Copenh); 1990 Jan; 122(1):37-40. PubMed ID: 2106188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E; Goffi S; Arvat E; Nicolosi M; Procopio M; Bellone J; Imperiale E; Mazza E; Baracchi G; Camanni F
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.
    Kirk JM; Ross RJ; Trainer PJ; Froud AL; Davies SC; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1991 May; 34(5):407-11. PubMed ID: 2060150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic enhancement of pyridostigmine potentiates spontaneous diurnal but not nocturnal growth hormone secretion in short children.
    Ghigo E; Imperiale E; Mazza E; Goffi S; Procopio M; Müller EE; Camanni F
    Neuroendocrinology; 1989 Feb; 49(2):134-7. PubMed ID: 2498754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.
    Giustina A; Bossoni S; Bodini C; Cimino A; Pizzocolo G; Schettino M; Wehrenberg WB
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):510-7. PubMed ID: 1759540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men.
    Coiro V; Volpi R; Bertoni P; Finzi G; Marcato A; Caiazza A; Colla R; Giacalone G; Rossi G; Chiodera P
    Gerontology; 1992; 38(4):217-22. PubMed ID: 1358762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L; Marziani E; Manzoni P; Arvat E; Valetto MR; Gianotti L; Ghigo E; Chiumello G
    Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL; Wallace WH; Shalet SM
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated GH-releasing hormone administration unravels different GH secretory patterns in normal adults and children.
    Ghigo E; Goffi S; Mazza E; Arvat E; Procopio M; Bellone J; Müller EE; Camanni F
    Acta Endocrinol (Copenh); 1989 May; 120(5):598-601. PubMed ID: 2499148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A; Muruais C; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.
    Loche S; Pintor C; Cappa M; Ghigo E; Puggioni R; Locatelli V; Müller EE
    Acta Endocrinol (Copenh); 1989 May; 120(5):624-8. PubMed ID: 2499149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ; Iglesias P; Selgas R; Bajo MA; Aguilera A
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
    Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E; Gianotti L; Ragusa L; Valetto MR; Cappa M; Aimaretti G; Ramunni J; Grottoli S; Camanni F; Ghigo E
    Dementia; 1996; 7(5):288-92. PubMed ID: 8872421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.